Survival after complete surgical resection of multiple metastases from renal cell carcinoma

Cancer

Volumn 117, Issue 13, 2011, Pages 2873-2882

  Alt, Angela L ^a   Boorjian, Stephen A ^a   Lohse, Christine M ^b   Costello, Brian A ^b   Leibovich, Bradley C ^a   Blute, Michael L ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

kidney cancer; metastasectomy; metastases; nephrectomy; renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS RESECTION; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953848961     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25836     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E., Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Pantuck AJ, Zisman A, Belldegrun AS., The changing natural history of renal cell carcinoma. J Urol. 2001; 166: 1611-1623.
3. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P., A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001; 166: 63-67. (Pubitemid 32565343)
4. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005; 173: 48-51. (Pubitemid 39627669)
5. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559-4566. (Pubitemid 35402959)
6. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M., Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296. (Pubitemid 34032623)
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated M results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27: 3312-3318.
9. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G., High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997; 3: S70-S72.
10. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC., Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688-696.
11. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P., Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008; 180: 873-878.
12. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS., Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998; 16: 2261-2266. (Pubitemid 28265066)
13. Kierney PC, van Heerden JA, Segura JW, Weaver AL., Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol. 1994; 1: 345-352.
14. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005; 174: 1759-1763. (Pubitemid 41546928)
15. Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010; 57: 317-325.
16. Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006; 95: 691-698. (Pubitemid 44373483)
17. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM., Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol. 1999; 3: 197-203. (Pubitemid 29108145)
18. Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009; 104: 456-460.
19. Kwak C, Park YH, Jeong CW, Lee SE, Ku JH., No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? Urol Oncol. 2007; 25: 310-316. (Pubitemid 47031000)
20. Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H., Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002; 73: 1082-1087. (Pubitemid 34275883)
21. Reddy S, Wolfgang CL., The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009; 10: 287-293.
22. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML., Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol. 2008; 180: 99-103.
23. Murthy SK, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005; 79: 996-1003. (Pubitemid 40288764)
24. Friedel G, Hurtgen M, Penzenstadler M, Kyriss T, Toomes H., Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res. 1999; 19: 1593-1596. (Pubitemid 29255654)
25. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H., Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002; 74: 1653-1657. (Pubitemid 35222660)
26. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 1994; 57: 339-344. (Pubitemid 24101129)
27. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE., Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005; 48: 77-81. (Pubitemid 40835595)
28. Jackson RJ, Loh SC, Gokaslan ZL., Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg. 2001; 94: 18-24. (Pubitemid 32799706)
29. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol. 2000; 164: 1505-1508.
30. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007; 89: 1794-1801. (Pubitemid 47229888)
31. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol. 2003; 10: 705-710. (Pubitemid 40486904)
32. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008; 113: 1641-1648.
33. Wronski M, Arbit E, Russo P, Galicich JH., Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996; 47: 187-193. (Pubitemid 26075272)
34. Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int. 2006; 97: 505-508.
35. Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP., Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol. 2002; 167: 1630-1633. (Pubitemid 34240687)
36. Master VA, Gottschalk AR, Kane C, Carroll PR., Management of isolated renal fossa recurrence following radical nephrectomy. J Urol. 2005; 174: 473-477. (Pubitemid 40981577)
37. Edge SB, Byrd DR, Comptom CC, et al, eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010.
38. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 987-989.
39. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM., Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001; 166: 68-72. (Pubitemid 32565344)
40. Russo P, Synder M, Vickers A, Kondagunta V, Motzer R., Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal. 2007; 7: 768-778.
41. Golimbu M, Al-Askari S, Tessler A, Morales P., Aggressive treatment of metastatic renal cancer. J Urol. 1986; 136: 805-807. (Pubitemid 16026219)
42. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB., Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005; 28: 488-495. (Pubitemid 41232570)
43. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J., Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. (Pubitemid 29368255)
44. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454-463. (Pubitemid 41079774)
45. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P., Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006; 24: 3101-3106. (Pubitemid 46638947)
46. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010; 28: 1502-1507.
47. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009; 181: 518-523.
48. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol. 2009; 182: 881-886.
49. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [serial online]. J Transl Med. 2007; 5: 32.